Caribou Biosciences, Inc. (NASDAQ:CRBU) Position Boosted by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its stake in Caribou Biosciences, Inc. (NASDAQ:CRBU) by 19.0% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 739,530 shares of the company’s stock after buying an additional 118,325 shares during the period. Charles Schwab Investment Management Inc. owned 0.82% of Caribou Biosciences worth $1,449,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Bank of New York Mellon Corp raised its holdings in shares of Caribou Biosciences by 14.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 308,273 shares of the company’s stock worth $506,000 after purchasing an additional 38,098 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Caribou Biosciences by 15.2% in the 2nd quarter. American Century Companies Inc. now owns 125,029 shares of the company’s stock valued at $205,000 after acquiring an additional 16,530 shares in the last quarter. Bruce & Co. Inc. boosted its stake in Caribou Biosciences by 50.0% in the 2nd quarter. Bruce & Co. Inc. now owns 300,000 shares of the company’s stock worth $492,000 after purchasing an additional 100,000 shares during the period. Dimensional Fund Advisors LP grew its position in Caribou Biosciences by 25.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock worth $4,302,000 after purchasing an additional 536,162 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in Caribou Biosciences during the 2nd quarter worth about $2,432,000. Institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Price Performance

CRBU opened at $1.91 on Tuesday. Caribou Biosciences, Inc. has a one year low of $1.50 and a one year high of $8.33. The stock has a market capitalization of $172.96 million, a P/E ratio of -1.16 and a beta of 2.27. The company’s 50 day simple moving average is $2.09 and its 200-day simple moving average is $2.03.

Caribou Biosciences (NASDAQ:CRBU) last issued its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. The firm had revenue of $2.02 million for the quarter, compared to analysts’ expectations of $3.37 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. As a group, analysts anticipate that Caribou Biosciences, Inc. will post -1.64 EPS for the current year.

Analysts Set New Price Targets

CRBU has been the subject of several research reports. Citigroup reduced their price target on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, November 26th. HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of Caribou Biosciences in a research note on Friday, November 15th. Four equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $10.20.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.